JP2020537544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537544A5 JP2020537544A5 JP2020540683A JP2020540683A JP2020537544A5 JP 2020537544 A5 JP2020537544 A5 JP 2020537544A5 JP 2020540683 A JP2020540683 A JP 2020540683A JP 2020540683 A JP2020540683 A JP 2020540683A JP 2020537544 A5 JP2020537544 A5 JP 2020537544A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- itr
- raav
- expression construct
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000019204 Progranulins Human genes 0.000 claims description 8
- 108010012809 Progranulins Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 26
- 239000013608 rAAV vector Substances 0.000 claims 16
- 241000702421 Dependoparvovirus Species 0.000 claims 13
- 239000013598 vector Substances 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 108700019146 Transgenes Proteins 0.000 claims 7
- 108090000565 Capsid Proteins Proteins 0.000 claims 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims 6
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims 3
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims 3
- 108010006025 bovine growth hormone Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 230000001124 posttranscriptional effect Effects 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 241000701447 unidentified baculovirus Species 0.000 claims 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 7
- 101710114165 Progranulin Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 3
- 102100037632 Progranulin Human genes 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007752A JP7389828B2 (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
| JP2022007736A JP7336730B2 (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567310P | 2017-10-03 | 2017-10-03 | |
| US201762567296P | 2017-10-03 | 2017-10-03 | |
| US201762567301P | 2017-10-03 | 2017-10-03 | |
| US201762567319P | 2017-10-03 | 2017-10-03 | |
| US201762567311P | 2017-10-03 | 2017-10-03 | |
| US62/567,319 | 2017-10-03 | ||
| US62/567,310 | 2017-10-03 | ||
| US62/567,301 | 2017-10-03 | ||
| US62/567,296 | 2017-10-03 | ||
| US62/567,311 | 2017-10-03 | ||
| PCT/US2018/054227 WO2019070894A1 (en) | 2017-10-03 | 2018-10-03 | GENE THERAPIES FOR LYSOSOMIAL DISORDERS |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007736A Division JP7336730B2 (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
| JP2022007752A Division JP7389828B2 (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537544A JP2020537544A (ja) | 2020-12-24 |
| JP2020537544A5 true JP2020537544A5 (https=) | 2021-11-11 |
| JP7361037B2 JP7361037B2 (ja) | 2023-10-13 |
Family
ID=65994362
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540683A Active JP7361037B2 (ja) | 2017-10-03 | 2018-10-03 | ライソゾーム病の遺伝子治療 |
| JP2022007752A Active JP7389828B2 (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
| JP2022007736A Active JP7336730B2 (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007752A Active JP7389828B2 (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
| JP2022007736A Active JP7336730B2 (ja) | 2017-10-03 | 2022-01-21 | ライソゾーム病の遺伝子治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11993790B2 (https=) |
| EP (1) | EP3692158A4 (https=) |
| JP (3) | JP7361037B2 (https=) |
| KR (3) | KR102700963B1 (https=) |
| CN (3) | CN112481269A (https=) |
| AU (3) | AU2018346105C1 (https=) |
| BR (1) | BR112020006661A2 (https=) |
| CA (1) | CA3078464A1 (https=) |
| IL (3) | IL273771B2 (https=) |
| MX (3) | MX2020003965A (https=) |
| WO (1) | WO2019070894A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| CN112501208A (zh) | 2017-10-03 | 2021-03-16 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| BR112020006661A2 (pt) | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| AU2018346104B2 (en) | 2017-10-03 | 2023-07-27 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| KR20210148101A (ko) | 2019-02-04 | 2021-12-07 | 프리라인 테라퓨틱스 리미티드 | 폴리뉴클레오티드 |
| BR112021015817A2 (pt) | 2019-02-22 | 2021-10-13 | The Trustees Of The University Of Pennsylvania | Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn |
| EP3931337A1 (en) * | 2019-02-26 | 2022-01-05 | The Trustees of The University of Pennsylvania | Compositions useful in treatment of krabbe disease |
| CA3136004A1 (en) * | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| GB201913974D0 (en) * | 2019-09-27 | 2019-11-13 | King S College London | Vector |
| MX2022004812A (es) * | 2019-10-22 | 2023-02-23 | Applied Genetic Tech Corporation | Sistemas de virus adeno-asociados (aav) para el tratamiento de enfermedades o trastornos neurodegenerativos asociados a la progranulina. |
| AU2020395327A1 (en) * | 2019-12-05 | 2022-07-21 | Cornell University | Stabilization of retromer for the treatment of Alzheimer's disease and other neurodegenerative disorders |
| WO2021163681A2 (en) * | 2020-02-14 | 2021-08-19 | The Trustees Of Columbia University In The City Of New York | Combination of retromer pharmacological chaperones and exogenous retromer for the treatment of alzheimer's disease and other neurodegenerative diseases and disorders |
| CA3177924A1 (en) * | 2020-05-12 | 2021-11-18 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of krabbe disease |
| CA3186207A1 (en) * | 2020-07-23 | 2022-01-27 | Rachel BAILEY | Optimized slc13a5 genes and expression cassettes and their use |
| BR112023001456A2 (pt) * | 2020-07-27 | 2023-04-11 | Voyager Therapeutics Inc | Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase |
| KR20230042513A (ko) | 2020-07-29 | 2023-03-28 | 프리라인 테라퓨틱스 리미티드 | 폴리펩티드 |
| BR112023001788A2 (pt) * | 2020-08-03 | 2023-02-23 | Prevail Therapeutics Inc | Vetores aav que codificam parkina e usos da mesma |
| JP2023537903A (ja) | 2020-08-10 | 2023-09-06 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害に対する遺伝子療法 |
| AU2021325891A1 (en) * | 2020-08-10 | 2023-04-06 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disorders |
| WO2022082178A2 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
| MX2023004420A (es) | 2020-10-15 | 2023-07-05 | Prevail Therapeutics Inc | Composiciones de virus adenoasociados recombinantes y métodos para su producción. |
| EP4229213A1 (en) | 2020-10-15 | 2023-08-23 | Prevail Therapeutics, Inc. | Assay for measuring potency of gene therapy drug product |
| EP4284442A4 (en) * | 2021-02-01 | 2025-04-23 | The Trustees of The University of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING NIEMANN PICK DISEASE TYPE A |
| US20240325506A1 (en) * | 2021-06-23 | 2024-10-03 | Avrobio, Inc. | Compositions and methods for treatment of gaucher disease |
| US20250049955A1 (en) | 2021-11-17 | 2025-02-13 | Voyager Therapeutics, Inc. | Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| JP1727698S (ja) * | 2021-12-20 | 2022-10-19 | ゴルフボールケース | |
| EP4511482A4 (en) * | 2022-04-19 | 2026-03-18 | Shanghai Vitalgen Biopharma Co Ltd | Recombinant AAV vectors for the treatment of neurodegenerative disorders |
| EP4598940A1 (en) | 2022-10-04 | 2025-08-13 | Eli Lilly and Company | Gene therapy for trem2-associated diseases and disorders |
| CN118715316B (zh) * | 2022-10-08 | 2025-09-19 | 凌意(杭州)生物科技有限公司 | 用于治疗GCase缺乏相关疾病的多核苷酸 |
| GB202216168D0 (en) | 2022-10-31 | 2022-12-14 | UCB Biopharma SRL | Route of administration |
| AU2023427408A1 (en) * | 2023-02-02 | 2025-09-04 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| JP2026509301A (ja) | 2023-03-14 | 2026-03-17 | ユーシービー バイオファルマ エスアールエル | 遺伝子治療 |
| WO2025039622A1 (zh) * | 2023-08-23 | 2025-02-27 | 上海金珂博生物技术有限公司 | 经修饰的腺相关病毒载体及其在治疗中枢神经系统疾病中的用途 |
| CN118086341B (zh) * | 2024-04-25 | 2024-08-02 | 上海凌医生物科技有限公司 | 在肝脏中高表达人源葡萄糖脑苷脂酶基因的表达框 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6182035A (ja) * | 1984-09-27 | 1986-04-25 | Toshiba Corp | 制振装置 |
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US5490559A (en) * | 1994-07-20 | 1996-02-13 | Dinulescu; Horia A. | Heat exchanger with finned partition walls |
| US20020068285A1 (en) * | 1996-01-11 | 2002-06-06 | Frudakis Tony N. | Compositions and methods for the therapy and diagnosis of breast cancer |
| WO1998009524A1 (en) | 1996-09-06 | 1998-03-12 | Chiron Corporation | Methods and compositions for liver specific delivery of therapeutic molecules using recombinant aav vectors |
| US6538119B2 (en) | 1997-11-18 | 2003-03-25 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| EP1112090A2 (en) | 1998-09-09 | 2001-07-04 | Myelos Corporation | Method of stimulating prosaposin receptor activity |
| EP1121429A2 (en) | 1998-10-16 | 2001-08-08 | Introgene B.V. | Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| US6696272B1 (en) | 1999-06-02 | 2004-02-24 | Hsc Research & Development Limited Partnership | Products and methods for gaucher disease therapy |
| DE19937800B4 (de) * | 1999-08-10 | 2005-06-16 | Gea Energietechnik Gmbh | Anlage zur Kondensation von Dampf |
| AU5323301A (en) | 2000-04-06 | 2001-10-23 | Kos Pharma Inc | Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia |
| GB0009887D0 (en) | 2000-04-20 | 2000-06-07 | Btg Int Ltd | Cytotoxic agents |
| US7056502B2 (en) | 2000-04-28 | 2006-06-06 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids |
| JP2004516016A (ja) * | 2000-09-18 | 2004-06-03 | ジェンザイム・コーポレイション | ハイブリッドユビキチンプロモーターを含む発現ベクター |
| US7232670B2 (en) | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| US20030133924A1 (en) | 2001-12-21 | 2003-07-17 | Novazyme Pharmaceuticals, Inc. | Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease |
| AU2003221733A1 (en) | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
| US6691742B1 (en) * | 2003-04-25 | 2004-02-17 | Thomas L. Cooper | Method and apparatus for supporting a pipe |
| EP1620133B1 (en) | 2003-05-01 | 2015-12-09 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
| WO2005049676A1 (de) * | 2003-11-21 | 2005-06-02 | Basf Aktiengesellschaft | Polyalkylenoxidgruppen und quartäre stickstoffatome enthaltende copolymere |
| CN101443046A (zh) * | 2004-06-23 | 2009-05-27 | 建新公司 | 治疗多囊病的方法和组合物 |
| WO2006036465A2 (en) | 2004-09-03 | 2006-04-06 | University Of Florida | Compositions and methods for treating cystic fibrosis |
| CA2580189C (en) | 2004-09-29 | 2013-05-21 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
| AU2006254796B2 (en) | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| EP2687223B2 (en) | 2006-05-30 | 2024-11-20 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
| US8486635B2 (en) | 2006-05-30 | 2013-07-16 | Mayo Foundation For Medical Education And Research | Detecting and treating dementia |
| HUE031156T2 (en) | 2006-06-07 | 2017-06-28 | Genzyme Corp | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| DE102006029773B3 (de) * | 2006-06-27 | 2007-07-12 | Gea Energietechnik Gmbh | Verfahren zur Errichtung einer Kondensationsanlage |
| CN101583621A (zh) * | 2006-07-20 | 2009-11-18 | 诺华有限公司 | 治疗、诊断或检测癌症的amigo-2抑制剂 |
| EP2145014B1 (en) | 2007-04-05 | 2012-12-12 | The J. David Gladstone Institutes | Agents that reduce neuronal overexcitation |
| WO2008143797A1 (en) | 2007-05-11 | 2008-11-27 | Genzyme Corporation | Methods of producing a secreted protein |
| EP2154969B1 (en) | 2007-05-16 | 2015-11-18 | The Brigham and Women's Hospital, Inc. | Treatment of synucleinopathies |
| CA2692171C (en) * | 2007-06-22 | 2019-10-22 | Randolph Watnick | Methods and uses thereof of prosaposin |
| WO2011084685A2 (en) * | 2009-12-17 | 2011-07-14 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
| US20090176729A1 (en) | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| WO2009089635A1 (en) | 2008-01-16 | 2009-07-23 | Neurodyn, Inc. | Treating neurodegenerative diseases with progranulin (pgrn) |
| US9265843B2 (en) * | 2008-03-27 | 2016-02-23 | The Ohio State University | Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor |
| HRP20250897T1 (hr) | 2009-05-02 | 2025-09-26 | Genzyme Corporation | Genska terapija za neurodegenerativne poremećaje |
| US9255266B2 (en) | 2009-05-06 | 2016-02-09 | Rutgers, The State University Of New Jersey | RNA targeting in alpha-synucleinopathies |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| EP2561073B1 (en) | 2010-04-23 | 2016-08-24 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| US9290759B2 (en) | 2010-08-25 | 2016-03-22 | The Trustees Of Columbia University In The City Of New York | Optimized miRNA constructs |
| WO2012027713A2 (en) | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| WO2012057363A1 (ja) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
| JP6312436B2 (ja) | 2010-11-16 | 2018-04-18 | ニューロダイン ライフ サイエンシズ インコーポレイテッドＮｅｕｒｏｄｙｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | ネプリライシンの発現および活性を増大させるための方法および医薬組成物 |
| DK3081568T3 (da) | 2011-05-09 | 2020-02-24 | Eip Pharma Llc | Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| CN104540952A (zh) | 2012-05-18 | 2015-04-22 | 衣阿华大学研究基金会 | 用于治疗淀粉状蛋白沉积的方法和组合物 |
| EP3196301B1 (en) | 2012-07-11 | 2018-10-17 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of monogenic diseases |
| US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
| AU2013337354A1 (en) | 2012-11-05 | 2015-05-21 | Genzyme Corporation | Compositions and methods for treating proteinopathies |
| WO2014168953A1 (en) | 2013-04-08 | 2014-10-16 | University Of Iowa Research Foundation | Chimeric adeno-associated virus/ bocavirus parvovirus vector |
| CN115120746A (zh) | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
| US9347107B2 (en) | 2013-05-23 | 2016-05-24 | Norman Z Lai | Vector containing multiple nucleotide sequences for the expression of enzymes |
| US9951330B2 (en) | 2013-07-11 | 2018-04-24 | The Trustees Of Columbia University In The City Of New York | Micrornas that silence tau expression |
| US9574184B2 (en) | 2013-09-25 | 2017-02-21 | Children's Hospital Medical Center | Lysosomal protein targeting sequence and therapeutic applications of same |
| CA2955086A1 (en) * | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| MA40460A (fr) * | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisation correspondante |
| GB2558326B (en) * | 2014-09-05 | 2021-01-20 | Population Bio Inc | Methods and compositions for inhibiting and treating neurological conditions |
| US10900053B2 (en) * | 2014-11-21 | 2021-01-26 | University Of Florida Research Foundation, Incorporated | Genome-modified recombinant adeno-associated virus vectors |
| EP3050953B1 (en) | 2015-02-02 | 2018-12-26 | The Procter and Gamble Company | Detergent composition |
| US10513701B2 (en) | 2015-03-25 | 2019-12-24 | Università Degli Studi Di Trento | RNA interference mediated therapy for neurodegenerative diseases |
| US20170035860A1 (en) | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
| EP3285788B1 (en) * | 2015-04-23 | 2024-12-18 | University of Massachusetts | Modulation of aav vector transgene expression |
| CA2985235A1 (en) | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
| EP3091087A1 (en) | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| HK1256341A1 (zh) | 2015-05-15 | 2019-09-20 | 明尼苏达大学董事会 | 用於治疗性递送到中枢神经系统的腺相关物 |
| WO2017058561A1 (en) | 2015-10-02 | 2017-04-06 | The Procter & Gamble Company | Cleaning pad, cleaning implement, and a method of improving shine of a hard surface using the cleaning pad or cleaning implement with a cleaning composition |
| MX2018004755A (es) | 2015-10-29 | 2018-12-19 | Voyager Therapeutics Inc | Entrega de polinucleotidos dirigidos al sistema nervioso central. |
| SG11201802408RA (en) | 2015-11-05 | 2018-05-30 | Bamboo Therapeutics Inc | Modified friedreich ataxia genes and vectors for gene therapy |
| CA3011939A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| EP3411484B1 (en) | 2016-02-05 | 2023-10-04 | Emory University | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid |
| WO2017147509A1 (en) | 2016-02-25 | 2017-08-31 | Marco Colonna | Compositions comprising trem2 and methods of use thereof |
| US20190328906A1 (en) | 2016-03-02 | 2019-10-31 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
| ES2802454T3 (es) * | 2016-04-08 | 2021-01-19 | Procter & Gamble | Composición de limpieza para lavavajillas |
| EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CN112501208A (zh) | 2017-10-03 | 2021-03-16 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| BR112020006661A2 (pt) | 2017-10-03 | 2020-10-13 | Prevail Therapeutics, Inc. | terapias de genes para distúrbios lipossomais |
| AU2018346104B2 (en) | 2017-10-03 | 2023-07-27 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| US20200283800A1 (en) | 2017-10-23 | 2020-09-10 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative diseases |
| BR112020008033A2 (pt) | 2017-10-23 | 2020-10-27 | Prevail Therapeutics, Inc. | terapias gênicas para doença neurodegenerativa |
| JP7616995B2 (ja) | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| CA3136004A1 (en) * | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| WO2020210615A1 (en) | 2019-04-10 | 2020-10-15 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| US20220211871A1 (en) | 2019-04-10 | 2022-07-07 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス，インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| AU2021325891A1 (en) | 2020-08-10 | 2023-04-06 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disorders |
-
2018
- 2018-10-03 BR BR112020006661-3A patent/BR112020006661A2/pt unknown
- 2018-10-03 KR KR1020227002135A patent/KR102700963B1/ko active Active
- 2018-10-03 CN CN202011196199.1A patent/CN112481269A/zh active Pending
- 2018-10-03 WO PCT/US2018/054227 patent/WO2019070894A1/en not_active Ceased
- 2018-10-03 CA CA3078464A patent/CA3078464A1/en active Pending
- 2018-10-03 KR KR1020207012190A patent/KR102697811B1/ko active Active
- 2018-10-03 EP EP18864729.1A patent/EP3692158A4/en active Pending
- 2018-10-03 KR KR1020227002136A patent/KR102709597B1/ko active Active
- 2018-10-03 US US16/753,322 patent/US11993790B2/en active Active
- 2018-10-03 CN CN202011191794.6A patent/CN112553210B/zh active Active
- 2018-10-03 AU AU2018346105A patent/AU2018346105C1/en active Active
- 2018-10-03 MX MX2020003965A patent/MX2020003965A/es unknown
- 2018-10-03 JP JP2020540683A patent/JP7361037B2/ja active Active
- 2018-10-03 IL IL273771A patent/IL273771B2/en unknown
- 2018-10-03 CN CN201880075846.8A patent/CN111492061A/zh active Pending
-
2019
- 2019-11-21 US US16/690,320 patent/US10689625B2/en active Active
-
2020
- 2020-04-06 US US16/841,539 patent/US11661585B2/en active Active
- 2020-06-18 US US16/904,909 patent/US11655460B2/en active Active
- 2020-07-13 MX MX2020011747A patent/MX2020011747A/es unknown
- 2020-07-13 MX MX2020011746A patent/MX2020011746A/es unknown
- 2020-10-29 AU AU2020260485A patent/AU2020260485B2/en not_active Ceased
- 2020-10-29 AU AU2020260491A patent/AU2020260491B2/en not_active Ceased
-
2021
- 2021-01-03 IL IL279931A patent/IL279931A/en unknown
- 2021-01-03 IL IL279930A patent/IL279930A/en unknown
-
2022
- 2022-01-21 JP JP2022007752A patent/JP7389828B2/ja active Active
- 2022-01-21 JP JP2022007736A patent/JP7336730B2/ja active Active
-
2023
- 2023-04-11 US US18/298,529 patent/US12570963B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537544A5 (https=) | ||
| JP2020537542A5 (https=) | ||
| JP2020537543A5 (https=) | ||
| JP2022060228A5 (https=) | ||
| CN101511373B (zh) | 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体 | |
| US11938197B2 (en) | Polynucleotides and vectors for the expression of transgenes | |
| JP2022511348A5 (https=) | ||
| IL273776B2 (en) | Gene therapies for lysosomal disorders | |
| Taschenberger et al. | A microRNA124 target sequence restores astrocyte specificity of gfaABC1D-driven transgene expression in AAV-mediated gene transfer | |
| JP2022549380A5 (https=) | ||
| KR20190032375A (ko) | 신규 아데노-관련 바이러스 캡시드 단백질 | |
| CN104520428A (zh) | 将基因转移到细胞、器官和组织的aav载体组合物和方法 | |
| US10016514B2 (en) | Polynucleotides, vectors and methods for insertion and expression of transgenes | |
| JP2022530833A (ja) | ポンペ病の治療のために有用な組成物 | |
| US20230049066A1 (en) | Novel aav3b variants that target human hepatocytes in the liver of humanized mice | |
| US20240318199A1 (en) | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders | |
| JP2023539247A (ja) | Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用 | |
| CN120641136A (zh) | 用于额颞叶痴呆的基因疗法 | |
| TW202229315A (zh) | 改良的腺相關病毒(aav)載體及其用途 | |
| CN116096904A (zh) | 改进的aav-abcd1构建体和用于治疗或预防肾上腺脑白质营养不良(ald)和/或肾上腺脊髓神经病(amn)的用途 | |
| CN120548368A (zh) | 用于正确包装重复元件的腺相关病毒载体 | |
| CN118414348A (zh) | 经修饰的aav衣壳和载体 | |
| US20240425879A1 (en) | Compositions and methods for adeno-associated (aav) virus dnase expression | |
| KR102874560B1 (ko) | 아데노연관바이러스 변이체 | |
| US12480098B1 (en) | Adeno-associated virus variant |